About Us

We deliver expertise, innovation & quality to molecular analysis

Our comprehensive molecular analysis laboratory is powered by the most advanced automated platforms, ready for all your bioanalytical needs.

Our Story

A History of Innovation

Mikael Kubista, an early adopter of quantitative PCR (qPCR), founded TATAA Biocenter in 2001 as a center of excellence in qPCR and gene expression analysis. It quickly became the world’s largest qPCR training provider, and later, Europe’s largest qPCR services provider.

It was the first laboratory in Europe to obtain flexible ISO 17025 certification and was presented the Frost & Sullivan Award for Customer Value Leadership as Best-in-Class Services for Analyzing Genetic Material in 2013.

In recent years, TATAA researchers contributed to significant scientific achievements, such as pioneering subcellular protein profiling (2018), contributing to multicenter evaluations of microRNA extraction from blood samples and circulating cell-free DNA extraction (2019), developing GrandPerformance Sars-CoV-2 Detection kit (CE-IVD) (2020), unravelling false positive covid testing (2020) and contributing to the first single cell multi-omics profiling study (2020).

Experts in molecular analysis


TATAA Biocenter founded as a university spin-off in Gothenburg, Sweden.

TATAA researchers characterize the reverse transcription of RT-qPCR providing guidelines.

TATAA publishes first dPCR study using a high throughput platform

TATAA becomes partner in the consortia SPIDIA(4P) supported by the EU to study the pre-analytical phase of molecular diagnostics and analysis.

Team of PCR opinion leaders including TATAA publishes the MIQE guidelines.

TATAA becomes the first bioanalytical lab in Europe with flexible ISO 17025 accreditation.

Team of PCR opinion leaders including TATAA publishes the digital MIQE guidelines.

TATAA launches high throughput protein profiling service.

TATAA introduces Next Generation Sequencing (NGS) service.

TATAA researchers publish how to assess mRNA quality and launch the RNA QC toolbox.

TATAA invents Two-Tailed PCR.

TATAA invents Direct Blood Genotyping (DBG).

TATAA launches new high-capacity, high-throughput laboratory and announces formation of in-house bioinformatics team.




Mikael has been interested in life sciences for as long as he can remember. He studied chemistry at University of Göteborg, Sweden, and obtained his B.Sc. in chemistry in 1984.

He then worked at Astra Hässle (today part of AstraZeneca), studying the K+/H+-ATPase inhibitor omeprazole, which became the bestselling pharmaceutical drug of its time for treating ulcers.

In 1988, he received his Ph.D. in physical chemistry for studies of nucleic acid interactions with polarized light spectroscopy. After post-doctoral studies on transcriptional foot-printing (Melbourne, Australia), and chromatin and epigenetic modulation of nucleosomes (Yale, USA), he started his own research group in Göteborg on DNA-ligand interactions. His group discovered a novel mechanism of transcriptional activation of oncogenes, which led to the development of a new class of anticancer drugs targeting specific quadruplex DNA structures. Mikael’s team also developed methods for multidimensional data analysis (based on which MultiD Analyses AB was founded), and invented the light-up probes for nucleic acid detection in homogeneous solution, which led to the foundation of LightUp Technologies AB as Europe’s first company focused on quantitative real-time PCR (qPCR)-based diagnostics.

In 2001, Mikael founded TATAA Biocenter as a center of excellence in qPCR and gene expression analysis, initially as a molecular analyis training center and later as a bioanalytics service and high-quality reagent provider.

During his career, Mikael has registered 21 patents and has founded five biotechnology start-up companies. He has also authored over 170 original research papers and 19 reviews in international peer-review journals that have been cited more than 15,000 times. Mikael also co-authored the MIQE guidelines for RT-qPCR analysis, which receives an average of 25 citations per week, and is a member of the CEN/ISO group drafting guidelines for the pre-analytical process in molecular diagnostics.

Your Order0
There is nothing to show!

Sign up for our newsletter?

Subscribe for exclusive offers and updates on new arrivals

"*" indicates required fields